Pharmacokinetics and relative bioavailability of antidepressant GSB-106 (hexamethylendiamide bis-(N-monosuccinyl-L-seryl-L-lysine) were determined in rabbits after single oral administration of the pharmaceutical substance and tablet mass. GSB-106 concentrations in the blood plasma were determined by HPLC-mass spectrometry. Relative bioavailability of GSB-106 tablet form was 160.79±24.33%.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10517-019-04587-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Creation of Long-Term Physical Stability of Amorphous Solid Dispersions N-Butyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazine-3-carboxamide, Resistant to Recrystallization Caused by Exposure to Moisture.
Materials (Basel)
January 2025
Institute of Pharmacy and Biotechnology, Peoples' Friendship University of Russia n.a. P. Lumumba (RUDN), 6 Miklukho-Maklaya Str., 117198 Moscow, Russia.
Amorphous solid dispersion (ASD) technology is often used as a promising strategy to improve the solubility of active pharmaceutical ingredients (APIs). ASDs allow APIs to be dispersed at the molecular level in a polymer carrier, destroying the crystalline structure of the APIs and, thanks to the polymer, providing long-term supersaturation in solution. However, stability issues are an obstacle to the development of new medications with ASD.
View Article and Find Full Text PDFVenlafaxine loaded novasomes for intranasal delivery: Mucoadhesion, permeation and pharmacokinetics study.
J Pharm Sci
November 2024
Riphah Institute of Pharmaceutical Sciences (RIPS), Riphah International University Faisalabad, Faisalabad, Pakistan.
Depression is a mental disorder that often comes with symptoms like irritability, rage, changes in appetite or weight, hopelessness, and loss of interest in day-to-day activities. Venlafaxine (VLF) is a medication used to treat depression. When taken orally, only about 45 % of VLF enters the systemic circulation due to liver metabolism.
View Article and Find Full Text PDF, , and approaches for evaluating the preclinical DMPK profiles of ammoxetine, a novel chiral serotonin and norepinephrine reuptake inhibitor.
Front Pharmacol
November 2024
Guollence Pharmaceutical Technology Co., Ltd., Beijing, China.
Background And Aim: Ammoxetine, a novel chiral serotonin and norepinephrine reuptake inhibitor, holds promise for major depressive disorder treatment. This study aimed to thoroughly investigate its preclinical drug metabolism and pharmacokinetics (DMPK) profiles.
Methods: The preclinical DMPK profiles of ammoxetine were examined through , , and methods.
Berberine and Lung Cancer: From Pure Form to Its Nanoformulations.
Asia Pac J Clin Oncol
November 2024
Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
Lung cancer is the most fatal cancer worldwide. The etiology of lung cancer has yet to be fully characterized. Smoking and air pollution are several risk factors for lung cancer.
View Article and Find Full Text PDFChitosan Nanoparticles Embedded in In Situ Gel for Nasal Delivery of Imipramine Hydrochloride: Short-Term Stage Development and Controlled Release Evaluation.
Polymers (Basel)
October 2024
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutics and Medical Sciences, Petra University, Amman 11196, Jordan.
Imipramine hydrochloride (IMP), a tricyclic antidepressant used for major depression, enuresis, and neuropathic pain, is limited by gastrointestinal complications, low oral bioavailability (44%), and complex dosing requirements. This study aimed to explore a novel non-invasive nasal delivery system using chitosan nanoparticles (Cs NPs) embedded in an in situ gel to address the limitations of oral IMP administration. Cs NPs loaded with IMP were synthesized via ionic gelation and assessed for precision in drug concentration using a validated HPLC method.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!